45 abstracts found.
Results filter
- Session type: Clinical Trials Showcase Remove Filter
ABC-06 | A randomised phase III study of Active Symptom Control (ASC) with/without mFOLFOX after progression to Cisplatin-Gemcitabine chemotherapy for patients with advanced biliary tract cancers
Year: 2019
Session type: Clinical Trials Showcase
Optimizing Chemotherapy for Frail and Elderly Patients with Advanced Gastroesophageal Cancer (aGOAC): the GO2 Phase III Trial.
Year: 2019
Session type: Clinical Trials Showcase
BEACON: A Randomised, Phase 3 Study of Encorafenib and Cetuximab +/- Binimetinib vs. Choice of Either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E–Mutant Metastatic Colorectal Cancer Patients
Year: 2019
Session type: Clinical Trials Showcase
Capivasertib plus fulvestrant versus placebo plus fulvestrant in metastatic ER positive breast cancer (FAKTION): A randomised, double-blind, placebo-controlled, phase II trial
Year: 2019
Session type: Clinical Trials Showcase
Scheduling nab-paclItaxEl combined with GEmcitabine as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC) in the SIEGE randomised trial: a test of bench to bedside concept.
Year: 2017
Session type: Clinical Trials Showcase
Final DFS results of the SCOT study: An international Phase III Randomised (1:1) Non-inferiority Trial Comparing 3 months vs 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer
Year: 2017
Session type: Clinical Trials Showcase
Combined analysis of the FOXFIRE prospective randomised studies of first-line selective internal radiotherapy in patients with liver metastases from colorectal cancer
Year: 2017
Session type: Clinical Trials Showcase
Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial
Year: 2017
Session type: Clinical Trials Showcase
The NCRI Myeloma XI study: a large adaptive randomised clinical trial successfully answering a diverse range of key questions in multiple myeloma.
Year: 2017
Session type: Clinical Trials Showcase
Adjuvant capecitabine for biliary tract cancer (BTC): The UK BILCAP randomized study
Year: 2017
Session type: Clinical Trials Showcase
Perioperative chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: mature analysis of overall survival in the New EPOC randomised controlled trial
Year: 2017
Session type: Clinical Trials Showcase
Results of the OPARATIC trial: a phase I dose escalation study of olaparib in combination with temozolomide (TMZ) in patients with relapsed glioblastoma (GBM)
Year: 2017
Session type: Clinical Trials Showcase
Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE(NCT00268476)
Year: 2015
Session type: Clinical Trials Showcase
1University of Warwick, Coventry, UK,2MRC Clinical Trials Unit at UCL, London, UK,3Velindre Hospital, Cardiff, UK,4The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK,5Beatson West of Scotland Cancer Centre, Glasgow, UK,6Clatterbridge Cancer Centre, Wirral, UK,7South West Wales Cancer Institute, Swansea, UK,8University of Oxford Medical Oncology Department, Oxford, UK,9Royal Devon and Exeter NHS Foundation Trust, Exeter, UK,10Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK,11Belfast City Hospital, Belfast, UK,12Kantonsspital Chur, Chur, Switzerland,13Queen Elizabeth Hospital, Birmingham, UK,14The Christie and Salford Royal Hospitals, Manchester, UK,15Prostate Cancer Support Group, Middlesbrough, UK
CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy treatment-naïve patients (pts) with advanced melanoma (MEL)
Year: 2015
Session type: Clinical Trials Showcase
1Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA,2Oncology Institute of Veneto IRCCS, Padua, Italy,3University of Colorado Cancer Center, Denver, CO, USA,4Maria Sklodowska-Curie Memorial Cancer Center & Institute of Oncology, Warsaw, Poland,5Hospital de la Timone, Marseille, France,6Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA,7University of Michigan, Ann Arbor, MI, USA,8Department of Dermatology, University of Essen, Essen, Germany,9European Institute of Oncology, Milan, Italy,10Cross Cancer Institute, Edmonton, AB, Canada,11Universitäts Spital, Zurich, Switzerland,12Tasman Oncology Research, Queensland, Australia,13Netherlands Cancer Institute, Amsterdam, The Netherlands,14Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy,15Peter MacCallum Cancer Centre, Victoria, Australia,16Bristol-Myers Squibb, Princeton, NJ, USA,17Bristol-Myers Squibb, Wallingford, CT, USA,18Royal Marsden Hospital, London, UK,19Dana-Farber Cancer Institute, Boston, MA, USA
PET-NECK: A multi-centre, randomized, phase III, controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNSCC) treated with primary radical chemoradiotherapy (CRT)
Year: 2015
Session type: Clinical Trials Showcase
1InHANSE, University of Birmingham, Birmingham, UK,2Paul Strickland Scanner Centre, Mount Vernon Hospital, Middlesex, UK,3Warwick University Clinical Trials Unit, Coventry, UK,4Department of Cellular Pathology, Royal Victoria Infirmary, Newcastle, UK,5Queen Elizabeth Hospital Birmingham, Birmingham, UK,6Royal Marsden Hospital, London, UK,7HPV Oncology Group, Institute of Cancer Genetics, Cardiff University, Cardiff, UK,8Bristol Haematology and Oncology Centre, Bristol, UK,9Weston Park Hospital, Sheffield, UK,10Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK,11University of Leeds, Leeds, UK,12St James University Hospital, Leeds, UK
A phase II/III randomised trial comparing maintenance lapatinib vs placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer
Year: 2015
Session type: Clinical Trials Showcase
1Barts Cancer Institute, London, UK,2Guy’s and St Thomas’ Hospital NHS Trust, London, UK,3The Christie NHS Foundation Trust, Manchester, UK,4Beatson West of Scotland Cancer Centre, Glasgow, UK,5The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK,6University Hospital Southampton NHS Foundation Trust, Southampton, UK,7St James’s University Hospital, Leeds, UK,8Bristol Haematology and Oncology Centre, Bristol, UK,9Aberdeen Royal Infirmary, Aberdeen, UK,10Nottingham University Hospitals NHS Trust, Nottingham, UK,11Freeman Hospital, Newcastle, UK,12University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK,13Royal Marsden Hospital, Surrey, UK
Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): A phase III randomized trial (ALSYMPCA)
Year: 2011
Session type: Clinical Trials Showcase
Comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma: A Phase III randomised, open-label, multicentre trial (BRIM3)
Year: 2011
Session type: Clinical Trials Showcase
Optimal sequencing of adjuvant chemotherapy (CT) and radiotherapy (RT) for women with early breast cancer (EBC): results of the SECRAB trial. Presented on behalf of the SECRAB Steering Committee
Year: 2011
Session type: Clinical Trials Showcase
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukaemia and deletion of TP53: Final results of the National Cancer Research Institute (NCRI) CLL206 Trial
Year: 2011
Session type: Clinical Trials Showcase
Final analysis of intergroup randomized phase III study of androgen deprivation therapy (ADT) + radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110)
Year: 2012
Session type: Clinical Trials Showcase
The pattern and timing of disease recurrence in squamous cancer of the anus: Mature results from the NCRI ACT II trial
Year: 2012
Session type: Clinical Trials Showcase
Treatment of advanced neuroendocrine tumours: final results of the UKI NETS and NCRI randomised phase 2 NET 01 trial
Year: 2012
Session type: Clinical Trials Showcase
Phase III multi-centre, randomised, double-blind, placebo-controlled trial of gefitinib versus placebo in oesophageal cancer progressing after chemotherapy, COG (Cancer Oesophagus Gefitinib)
Year: 2012
Session type: Clinical Trials Showcase
A randomised clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in KRAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study
Year: 2013
Session type: Clinical Trials Showcase
A multicenter phase III randomised double-blind placebo controlled trial of pravastatin added to first-line standard chemotherapy in patients with small cell lung cancer (SCLC)
Year: 2013
Session type: Clinical Trials Showcase
Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma (HL) and a negative PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID trial
Year: 2013
Session type: Clinical Trials Showcase
Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial
Year: 2013
Session type: Clinical Trials Showcase
Prospective, multi-centre, case-control study to evaluate a novel Cytosponge™–TFF3 test for diagnosing Barrett’s oesophagus
Year: 2014
Session type: Clinical Trials Showcase
1MRC Cancer Unit, Hutchison/MRC Research Centre, Cambridge, UK,2Department Histopathology, Addenbrooke’s Hospital, Cambridge, UK,3University College London Hospital, London, UK,4Royal Victoria Infirmary, Newcastle upon Tyne, UK,5Nottingham Queen’s Medical Centre, Nottingham, UK,6Cancer Prevention Trials Unit, London, UK,7Multi-centre BEST2 Study group, England, UK
ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR)
Year: 2014
Session type: Clinical Trials Showcase
1Department of Oncology, University of Cambridge, Cambridge, UK,2NIHR Cambridge Biomedical Research Centre, Cambridge, UK,3Warwick Clinical Trials Unit, University of Warwick, Coventry, UK,4Cambridge Clinical Trials Unit − Cancer Theme, Cambridge, UK,5Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK,6Western General Hospital, Edinburgh, UK,7Peterborough City Hospital, Peterborough, UK,8Nottingham University Hospital City Campus, Nottingham, UK,9West Middlesex University Hospital, Isleworth, UK,10Royal Bournemouth Hospital, Bournemouth University, Bournemouth, UK,11Royal Surrey County Hospital, Guildford, UK,12Sandwell&West Birmingham NHS Trust; University Hospital Birmingham NHS Trust, Birmingham, UK,13Ontario Institute for Cancer Research, Ontario, Canada,14Edinburgh Cancer Research Centre, The University of Edinburgh, Edinburgh, UK,15Cancer Research UK Cambridge Research Institute, Cambridge, UK
REST- A Dutch/UK randomized phase III trial on the use of thoracic radiotherapy in extensive stage small-cell lung cancer
Year: 2014
Session type: Clinical Trials Showcase
1The Christie NHS Foundation Trust, Manchester, UK,2Weston Park Hospital, Sheffield, UK,3St James’s University Hospital, Leeds, UK,4Clatterbridge Centre for Oncology, Wirral, UK,5Bristol Haematology & Oncology Centre, Bristol, UK,6Northern Centre for Cancer Care, Freeman Hospital, Newcastle-upon-Tyne, UK,7James Cook University Hospital, Middlesbrough, UK,8Southampton General Hospital, Southampton, UK,9North Wales Cancer Centre, Glan Clwyd Hospital, Rhyl, UK,10Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK,11Netherlands Cancer Institute, Amsterdam, The Netherlands,12IKNL Clinical Research Department, Amsterdam, The Netherlands,13VU University Medical Center, Amsterdam, The Netherlands
ET: A randomised, multicentre, phase III trial to evaluate ERCC1 as a predictive biomarker for comparing platinum with nonplatinum chemotherapy, in patients with advanced/metastatic non-small cell lung cancer (NSCLC)
Year: 2014
Session type: Clinical Trials Showcase
1University College London Hospital, London, UK,2Christie Hospital Manchester, Manchester, UK,3Lincoln County Hospital, Lincoln, UK,4Royal Surrey County Hospital, Guildford, UK,5Leicester Royal Infirmary, Leicester, UK,6New Victoria Hospital, Kingston upon Thames, UK,7Calderdale & Huddersfield NHS Foundation Trust, Huddersfield, UK,8Guys Hospital London, London, UK,9North Devon District Hospital, Barnstaple, UK,10Princess Alexandra Hospital, Harlow, UK,11Aberdeen Royal Infirmary, Aberdeen, UK,12New Cross Hospital Birmingham, Birmingham, UK,13Charing Cross Hospital, London, UK,14Withybush General Hospital, Haverfordwest, UK,15University College London, London, UK
Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer
Year: 2009
Session type: Clinical Trials Showcase
Breakthrough Breast Cancer Research Unit, Kings College London School of Medicine, Guy's Hospital, London, UK
Results of ICON7: a phase III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Medical Research Council Cancer Trials Unit, presented on behalf of the GCIG ICON7 collaborators
Year: 2010
Session type: Clinical Trials Showcase
Results of BC2001: A 2×2 phase III randomised trial of synchronous chemo-radiotherapy (CRT) compared to radiotherapy (RT) alone and standard (sRT) versus reduced high-dose volume RT (rvRT) in muscle invasive bladder cancer (MIBC) (CRUK/01/004
Year: 2010
Session type: Clinical Trials Showcase
The MRC Myeloma IX Trial: beneficial effects of thalidomide and zoledronic acid for newly diagnosed myeloma patients of all ages
Year: 2010
Session type: Clinical Trials Showcase
Intergroup randomized controlled phase III trial of Androgen Deprivation Therapy (ADT) +/- Radiation Therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC, INT: T94-0110; NCT00002633)
Year: 2010
Session type: Clinical Trials Showcase